Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: A phase 3, double-blind, placebo-controlled, randomised trial

The Lancet Infectious Diseases

Volumn 11, Issue 4, 2011, Pages 284-292

  Marty, Francisco M ^a   Ljungman, Per ^b   Papanicolaou, Genovefa A ^c   Winston, Drew J ^d   Chemaly, Roy F ^e   Strasfeld, Lynne ^f   Young, Jo Anne H ^g   Rodriguez, Tulio ^h   Maertens, Johan ⁱ   Schmitt, Michael ^j   Einsele, Hermann ^k   Ferrant, Augustin ^l   Lipton, Jeffrey H ^m   Villano, Stephen A ⁿ   Chen, Hongzi ⁿ   Boeckh, Michael ^o  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UCLA MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^h LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j UNIVERSITY OF ULM   (Germany)

^k UNIVERSITY OF WÜRZBURG   (Germany)

^l CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^m PRINCESS MARGARET HOSPITAL   (Canada)

ⁿ ViroPharma Incorporated   (United States)

^o USA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BENZIMIDAVIR; FAMCICLOVIR; PLACEBO; VALACICLOVIR;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; BACTEREMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; HYPERTENSION; INFECTION PREVENTION; INFECTION RATE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TASTE DISORDER; VOMITING; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CANADA; CHEMOPREVENTION; CYTOMEGALOVIRUS INFECTIONS; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; RIBONUCLEOSIDES; STEM CELL TRANSPLANTATION; TRANSPLANTATION; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 79953035666     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70024-X     Document Type: Article

References (32)

1. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003, 9:543-558.
2. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
3. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995, 86:2815-2820.
4. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993, 118:173-178.
5. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med 1993, 118:179-184.
6. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002, 99:1159-1164.
7. Ljungman P, Deliliers GL, Platzbecker U, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood 2001, 97:388-392. for the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
8. Boeckh M, Ljungman P How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113:5711-5719.
9. Boeckh M, Nichols WG The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and pre-emptive therapy. Blood 2004, 103:2003-2008.
10. Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 2002, 46:2365-2372.
11. Williams SL, Hartline CB, Kushner NL, et al. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother 2003, 47:2186-2192.
12. Drew WL, Miner RC, Marousek GI, Chou S Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006, 37:124-127.
13. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008, 111:5403-5410.
14. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
15. Ljungman P, Griffiths P, Paya C Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
16. Lalezari JP, Aberg JA, Wang LH, et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother 2002, 46:2969-2976.
17. Lalezari JP, Aberg JA, Wang LH, et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother 2002, 46:2969-2976.
18. Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010, 12:489-496.
19. Griffiths P, Whitley R, Snydman DR, Singh N, Boeckh M Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007. Herpes 2008, 15:4-12.
20. Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997, 64:108-113.
21. Nakamae H, Kirby KA, Sandmaier BM, et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15:694-703.
22. Haynes RB, McKibbon KA, Wilczynski NL, Walter SD, Werre SR Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey. BMJ 2005, 330:1179.
23. Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB, Territo MC Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 2003, 36:749-758.
24. Ljungman P, de La Camara R, Milpied N, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002, 99:3050-3056.
25. Burns LJ, Miller W, Kandaswamy C, et al. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplant 2002, 30:945-951.
26. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994, 343:749-753.
27. Yahav D, Gafter-Gvili A, Muchtar E, et al. Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Eur J Cancer 2009, 45:3131-3148.
28. Ljungman P, de la Camara R, Cordonnier C, et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 2008, 42:227-240.
29. Meyers JD, Flournoy N, Thomas ED Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986, 153:478-488.
30. Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007, 110:490-500.
31. Fraser GA, Walker II Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations. Biol Blood Marrow Transplant 2004, 10:287-297.
32. Prentice RL Surrogate and mediating endpoints: current status and future directions. J Natl Cancer Inst 2009, 101:216-217.